SCHEMBL474946

SCHEMBL474946

Brc1nc2ccccc2o1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.54
RAB9A P51151 7/20 0.54
MAPT P10636 4/20 0.54
PSMB8 P28062 1/20 0.50
TP53 P04637 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
LMNA P02545 1/20 0.48
ALDH1A1 P00352 5/20 0.47
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 3/20 0.47
PKM P14618 2/20 0.47
KDM4E B2RXH2 2/20 0.47
GAA P10253 2/20 0.47
HCRTR1 O43613 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29531707 0.77 NPC1 (0.69) NPC1RAB9AMAPTPSMB8TP53
SCHEMBL824375 0.77 NPC1 (0.69) NPC1RAB9AMAPTPSMB8TP53
SCHEMBL10045305 0.76 NPC1 (0.54) NPC1RAB9AMAPTPSMB8TP53
SCHEMBL31590552 0.76 NQO2 (0.43) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL4679272 0.74 MAPT (0.61) NPC1RAB9AMAPTPSMB8TP53
SCHEMBL30011535 0.73 MAPT (0.47) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL28602639 0.73 MAPT (0.47) NPC1RAB9AMAPTTP53SMN1; SMN2
SCHEMBL5720494 0.73 NPC1 (0.50) NPC1RAB9AMAPTPSMB8TP53
SCHEMBL9542349 0.71 NPC1 (0.54) NPC1RAB9AMAPTPSMB8TP53
SCHEMBL1280187 0.71 NPC1 (0.54) NPC1RAB9AMAPTPSMB8TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114213383-B Method for catalytically synthesizing isocoumarin compounds by using ruthenium complex 上海应用技术大学 2023-03-31 CN claimed
CN-113185435-B Method for preparing beta-carbonyl sulfone compound by using half-sandwich iridium complex 上海应用技术大学 2022-11-15 CN claimed
CN-113527308-B Method for catalytic synthesis of 7-deazapurine compounds by using iron complex 上海应用技术大学 2022-10-14 CN claimed
CN-112538096-B Application of half-sandwich rhodium complex containing ortho-carboranyl benzoxazole structure 上海应用技术大学 2022-08-23 CN claimed
CN-114213383-A Method for catalytically synthesizing isocoumarin compounds by using ruthenium complex 上海应用技术大学 2022-03-22 CN claimed
CN-113527308-A Method for catalytic synthesis of 7-deazapurine compounds by using iron complex 上海应用技术大学 2021-10-22 CN claimed
CN-113185435-A Method for preparing beta-carbonyl sulfone compound by using half-sandwich iridium complex 上海应用技术大学 2021-07-30 CN claimed
CN-112538096-A Semi-sandwich rhodium complex with ortho-carborane benzoxazole structure and preparation method and application thereof 上海应用技术大学 2021-03-23 CN claimed
CN-110105404-B Ruthenium complex containing ortho-position carborane-based benzoxazole structure and preparation and application thereof 上海应用技术大学 2021-02-26 CN claimed
CN-111303423-A Polyimide substrate, manufacturing method thereof and display panel 武汉华星光电半导体显示技术有限公司 2020-06-19 CN claimed
CN-110105404-A The ruthenium complex of the benzoxazoles structure of carborane radical containing ortho position and its preparation and application 上海应用技术大学 2019-08-09 CN claimed
CN-103923765-A Detergent Composition For Process Of Manufacturing Semiconductors And Displays COWON INNOTECH INC 2014-07-16 CN claimed
JP-6100547-A None JP disclosed
EP-4648853-A1 TARGETED DEGRADATION OF VAV1 Monte Rosa Therapeutics AG (CH) 2025-11-19 EP disclosed
US-20250340539-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2025-11-06 US disclosed
US-12391659-B2 Benzothiazole and related compounds SPINOGENIX, INC. (US) 2025-08-19 US disclosed
EP-0081730-A1 Process for the preparation of hetaryloxyacetamides BAYER AG (DE) 1983-06-22 EP disclosed
EP-0060426-A2 N-(2,2,2-trifluoroethyl)-N-alkyl-azolyloxyacetic-acid amides, their preparation and use as herbicides and intermediates for their preparation BAYER AG (DE) 1982-09-22 EP disclosed
EP-0005501-B1 HETEROARYLOXY-ACETAMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES BAYER AG (DE) 1981-11-25 EP disclosed
EP-0005501-A2 Heteroaryloxy-acetamides, process for their preparation and their use as herbicides BAYER AG (DE) 1979-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12391659-B2 Benzothiazole and related compounds BACE1, APP, BACE2 NPC1 1283/4885RAB9A 1512/4885MAPT 5/4885
US-20250340539-A1 IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1, AND/OR CLK4 CLK1, CLK2, CLK3 NPC1 4313/4885RAB9A 2151/4885MAPT 312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.